

HOXA10 promotes nasopharyngeal carcinoma cell proliferation and invasion via inducing the expression of *ZIC2*

Z.-H. SHEN¹, K.-M. ZHAO², T. DU¹

¹Department of Nuclear Medicine, Yishui Central Hospital of Linyi, Linyi, Shandong, China

²Department of Obstetrics, Yishui Central Hospital of Linyi, Linyi, Shandong, China

Abstract. – **OBJECTIVE:** In this study, we aimed to explore the dysregulated genes in nasopharyngeal carcinoma (NPC) and to investigate the regulative effect of HOXA10 on ZIC2 expression and their involvement in NPC cell proliferation and invasion.

MATERIALS AND METHODS: Microarray data that compared the transcription profile of NPC tissues and normal tissues was searched in GEO datasets and was re-analyzed. The expression of HOXA10 and ZIC2 mRNA were retrieved in TCGA database. CNE1 and CNE2 cells were used as an in-vitro cell model. Luciferase reporters carrying truncated ZIC2 promoter sequences were generated to verify the predicted HOXA10 binding site. CCK-8 assay and transwell assay were applied to assess cell proliferation and invasion respectively.

RESULTS: HOXC6, HOXA3, and HOXA10 were upregulated in NPC tissues. Data mining in TCGA database showed that HOXA10, but not HOXC6 or HOXA3 is positively correlated to ZIC2 expression. Enforced HOXA10 expression significantly elevated ZIC2 expression at both mRNA and protein levels in both CNE1 and CNE2 cells. HOXA10 can directly bind to the promoter of ZIC2 and upregulate ZIC2 transcription. ZIC2 knockdown significantly reduced cell proliferation and invasion capability of CNE1 cells and also partly abrogated the effect of HOXA10 overexpression on enhancing cell proliferation and invasion.

CONCLUSIONS: Both HOXA10 and ZIC2 are upregulated in NPC tissues compared to the normal tissues. HOXA10 can increase ZIC2 expression via binding to the ZIC2 promoter. Functionally, the HOXA10-ZIC2 axis can enhance NPC cell proliferation and invasion.

Key Words:

HOXA10, Nasopharyngeal carcinoma, Proliferation, Invasion, ZIC2.

Introduction

Nasopharyngeal carcinoma (NPC) is the most common type of head and neck cancer in southern China and Southeastern Asia^{1,2}. The complex interactions among environmental factors, such as viral infections and other genetic factors synergistically drive the initiation and development of NPC^{3,4}. Although the standard combination of radiotherapy and chemotherapy has improved survival of the patients, management of NPC in advanced stages is still difficult⁵. The 5-year survival rate of stage III/IV disease is only around 55% due to local recurrence and distant metastasis⁶. Therefore, understanding the molecular mechanisms underlying NPC is necessary for future targeting therapy.

Homeoboxes (HOX) is a family of transcription factors that were involved in developmental control, while their dysregulations were also observed in a range of malignancies⁷. Homeobox A10 (HOXA10) is a transcription factor encoded by the *HOXA10* gene and is aberrantly expressed in some cancers. Its upregulation can promote pancreatic cancer cell invasion and MMP-3 expression via TGFβ2-mediated activation of the p38 MAPK pathway⁸. In some types of head and neck cancer, such as in oral squamous cell carcinoma, *HOXA10* upregulation drives growth, epithelial to mesenchymal transition (EMT) and invasion of the cancer cells^{9,10}. However, its role in NPC is not clear.

Zinc finger protein ZIC 2 (ZIC2) is also a transcription factor encoded by the *ZIC2* gene, which has C2H2 zinc fingers and can interact with multiple DNA and proteins¹¹. Recent studies reported that *ZIC2* acts as an oncogene in multiple cancers.

Its overexpression increases the growth rate and foci formation of epithelial ovarian cancer and stimulates anchorage-independent colony formation¹². *ZIC2* can also activate transcription of *OCT4* via recruiting the nuclear remodeling factor (NURF) complex to the *OCT4* promoter in liver cancer cells and thus drives the cancer stem cell (CSC) properties¹³.

In this study, we firstly reported that *HOXA10* can increase *ZIC2* expression in NPC cells via binding to the *ZIC2* promoter. Functionally, the *HOXA10*-*ZIC2* axis can enhance NPC cell proliferation and invasion.

Materials and Methods

Bioinformatic Data Mining

Microarray data that compared the transcription profile of NPC tissues and normal tissues were searched in GEO datasets. One available Affymetrix Human Genome U133 Plus 2.0 Array (accession: GDS3341) compared gene expression profile of 10 normal nasopharyngeal tissue and 31 NPC tissue samples. The raw data was downloaded and reanalyzed to identify the most upregulated genes in NPC tissues¹⁴.

The 100 upregulated genes and the upregulated HOX family transcription factors were loaded into the Search Tool for the Retrieval of Interacting Genes (STRING) (<http://string-db.org/>) database for analysis of protein-protein interaction (PPI) network. To ensure the high validity of the network, only experimentally validated interactions with a high confidence score ≥ 0.70 were included.

The expression profile of *HOXA10* in head and neck cancer tissues and the normal squamous epithelial and glandular cells were reviewed in Human Protein Atlas (<http://www.proteinatlas.org/>).

The expression of *ZIC2* mRNA and the expression of the dysregulated HOX family transcription factors, including *HOXC6*, *HOXA3* and *HOXA10* were retrieved in TCGA database, by using the UCSC Xena (<http://xena.ucsc.edu/>). The correlation between *HOXA10* and *ZIC2* was also analyzed using the UCSC Xena.

The *HOXA10* binding sites in the promoter region of *ZIC2* was predicted using the JASPAR Database (<http://jaspar.genereg.net/>).

Cell Culture and Transfection

Human NPC high differentiated cell line CNE1 and low differentiated cell line CNE2 cells were

obtained from the Experiment Animal Center of Sun Yat-Sen University. HEK-293 cells were obtained from ATCC. CNE1 and CNE2 cells were cultured in Roswell Park Memorial Institute 1640 (RPMI 1640), while HEK-293 cells were cultured in Dulbecco's modified Eagle's (DMEM) medium supplemented with 10% heat-inactivated fetal bovine serum, 100 $\mu\text{g/ml}$ streptomycin and 100 U/ml penicillin in an incubator with a humidified atmosphere and 5% CO_2 at 37°C.

Human *HOXA10* cDNA ORF clone (cat. RG202939) and the empty control pCMV6-AC-GFP vector (cat. PS100010) were obtained from OriGene (Rockville, MD, USA).

CNE1 and CNE2 cells were transiently transfected with either the cDNA ORF clone or the control vector using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). CNE1 cells without transfection and CNE1 cells 24 h after transfection of *HOXA10* cDNA ORF clone or the empty controls were infected the ready-to-use *ZIC2* shRNA (h) lentiviral particles (sc-45881-V, Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Western Blotting

The protein samples extracted from cell samples were loaded and separated on 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred to a polyvinylidene fluoride (PVDF) membrane. Then, the membranes were incubated with primary antibodies against *HOXA10* (ab180222, Abcam, Cambridge, UK), *ZIC2* (ab150404, Abcam) and anti- β -actin (ab3280, Abcam). Then, the membranes were washed and further incubated with secondary antibodies coupled to HRP. The blot signals were visualized using the SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA).

qRT-PCR Analysis

Total RNAs in the cell samples were extracted using the Trizol Reagent (Invitrogen). Then, the RNA samples were reverse-transcribed using the iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA) following the manufacturer's protocol. The mRNA level of *HOXA10* and *ZIC2* was measured using qRT-PCR analysis with the following primers (*HOXA10*: F, 5'-CTGGGCAATTCCAAAGGTGA-3' and R, 5'-ACTCTTTGCCGTGAGCCAGT-3'; *ZIC2*: F, 5'-TCCGAGAACCTCAAGATCC-3' and R, 5'-TAGGGCTTATCGGAGGTG-3') and the SYBR® Select Master Mix (Applied Biosystems,

Foster City, CA, USA) in an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems). β -Actin was detected as the endogenous control.

Plasmid Preparation

The promoter clone of *ZIC2* (NM_007129) was obtained from GeneCopoeia (Rockville, MD, USA; cat. HPRM19513). The detail promoter sequence was given in supplementary Table I. According to the prediction, HOXA10 has a conserved binding site located between -224 to -214 upstream the TSS site of *ZIC* promoter. To check whether HOXA10 has an effect on transcription activity of the promoter, five truncated promoter sequences, including -244 to +1013, -215 to +1013, -100 to +1013, and -50 to +1013 were PCR amplified from the promoter clone. After that, the truncated promoter sequences were inserted into the *XhoI-Hind III* site of the pGL3-basic luciferase reporter vector respectively.

Dual Luciferase Assay

HEK-293 cells were seeded into 12-well plates at a density of 2×10^5 cells per well and were further transfected with *HOXA10* cDNA ORF clone or the empty control. 24 h later, the cells were co-transfected the with 1.5 μ g luciferase construct plasmid or the empty reporter vector DNA and 0.05 μ g phRL-TK by using Superfectin (Qiagen, Valencia, CA, USA) and were further cultured

for another 24 h. Then, the luciferase activity of the cell lysate was quantified using the dual-luciferase reporter assay system with a luminometer (Promega, Madison, WI, USA) following the manufacturer's protocol.

CCK-8 Assay

NES1 cells with *HOXA10* overexpression or *ZIC2* knockdown alone or with *HOXA10* overexpression and *ZIC2* knockdown in combination were seeded in a 96-well plate (3×10^3 cells per well) and were further cultured for 3 days. Then, cell viability was measured by WST-8 assay using Cell Counting Kit-8 (CCK-8, Dojindo, Tokyo, Japan) following the manufacturer's protocol.

Transwell Assay

In Brief, 1×10^5 NES1 cells with *HOXA10* overexpression or *ZIC2* knockdown alone or with *HOXA10* overexpression and *ZIC2* knockdown in combination were suspended in 200 μ L serum-free RPMI-1640 medium and then plated into the upper chamber. The lower chamber was filled with RPMI-1640 supplemented with 20% FBS to create a chemoattractant environment. Then, the plates were cultured in a cell incubator for 24 h. After that, cells on the top surface of the insert were removed. The cells on the bottom surface were fixed with 4% polyoxymethylene and the number of invading cells were counted after staining with 0.1% crystal violet.

Supplementary Table I. The *ZIC2* promoter sequence.

```
>HPRM19513 NM_007129; name=ZIC2; Entrez_ID=7546; Genome=hg18; chr13+:99432076-99433333; TSS=99432320;
Upstream=244, Downstream=1013; Length=1257;
GAGAGGAAAAGGAGGAGACAAAAAATAAAAAATAAAAGGCTGCCGCTGCAGCGTTGGCGG
CGCCCATCGAAATCAACGGAGGCGGTGGCGAACGCAGCCACCGCAGCCGAGACCTGGGA
GCCCCCTGGGCTCACACTCCCTCGGGTCGCGGACTGCGCTGGGTCCACGCGCGCGGT
CACTAGTTCCGGGGCCAGCGCCAGGCCGACCGCGGGAGGGAGGAGGCGAGCGAGAGA
TCACTTTTTTATTGTTGTTATTGTTTTTCAGCCCAGCCTCCCCCTCCTCCCCCTCCCCCTG
CTCGCTTTCTCCCCCTCCACATCCCCCTCCCCCTACTCCCCCGCCTCCTCCTCCGGCAC
AACTTAAAGAAAGGGGGAGCGGCGCGGCTGCTGCCTTCATCTGGGGAAATTCGTGGCCAC
TGCAAGTTTACTACGCGAGGCGCAGCCAATGCCAAGCGCCGAGGCCGAGGAGGGCTAAAC
ACTGCGGCCGCGGCTCCGAACAATAACCGCCGCGCGCGGGCGGCGCGAGTAGGGCCGCG
GGGAGGGAGCTGTGCGCCGAGAGCGCCGCGGAGAGGACGCCTGGACTCCGCCTGCCGCC
CCGGCGCCCCCGCCGCGGTGAGGTGGAGCCGCTGGTGCGCTGGCCCCGGGTGCCGAGCGC
GGAGCTCGCCTCGGTCTCTCTCGCCCGTCTGCCTGGCGTGCGCACGGCCGCGCGGTT
GTGACTGCATTCTACCGCGCTGCTCGGTGCGGCGGGCTCCGGGTCCGCTGGGCGTGCG
AGTGAGTGTGTGCGTGCGCGCGCGGGTGCGCGCAGGGGTGGGGGCTGCGGCGCGGCGCTC
GCCCCCGGTAGCCCCCTCTCTCTCGGCTCCCCACACCTCCCTCCGGTCCCTCCTCC
CGCCCCCTGCCCTGCCCGCCCCGCCGAGCTCCTTAAATACACTTTGG
TTCTCCGCTGGCTTTGGACTCTTCTCTCTCTCCACCTCCTCCTCCTCCTCCCGCGCCG
CGCCTCCTCCTCTCTCTCTCTCGCGCCTTCGCTACGCGCCCGGCCCGCCGAGGCAGAT
CCAGGCGGCGGCGGAGGCGGCGGCGCAGGAGAGCGGCTCCAGGGCTGAAGTGCCGCC
ACCACCGCCGCTGCGCCTGGAGCCCGGTGGCCGCGGACGCACCGCGCGGATCGGGAGC
GGGAGTCGAGGCGGCGGAGGCGCAGGGCTCGCAGGGGCGGGCGGGCGCGCTGGCC
```




Figure 1. Bioinformatic analysis of the upregulated genes in NPC tissues compared to normal controls. **A**, Heat map of the upregulated genes in NPC tissues compared to normal controls. Data was obtained by re-analysis of the raw data of one available Affymetrix Human Genome U133 Plus 2.0 Array in GEO datasets (accession: GDS3341). The red frame indicates three upregulated HOX family transcription factor. **B**, PPI analysis of the interactions among the three HOX family transcription factors and the top 100 upregulated genes in NPC tissues by using the STRING database.

Statistical Analysis

Data were presented as means $\pm$ SD. All analyses were performed with SPSS software package (Version 19.0, SPSS Inc., Chicago, IL, USA). Data were analyzed for statistical significance by two-tailed Student's *t*-test or ANOVA with Student-Newman-Keuls test as a post hoc test. $p < 0.05$ was considered statistically significant.

Results

Bioinformatic Analysis of the Upregulated Genes in NPC tissues Compared to Normal controls

By analyzing the raw data of the microarray (GDS3341), we identified the most upregulated genes in 31 NPC tissue samples compared to 10 normal nasopharyngeal tissue (Figure 1A). Among the upregulated genes, we also observed three HOX family transcription factors, including HOXC6, HOXA3 and HOXA10 (Figure 1A, red frame). Then, we performed PPI analysis to check whether there is any known interactions among the three transcription factors and the top 100 upregulated genes in NPC tissues by using the STRING database. However, by limiting the evidence with high confidence score, we failed to identify any direct interaction (Figure 1B).

ZIC2 Expression is Positively Correlated to HOXA10 Expression in head and Neck Cancer

High *HOXA10* expression is associated more aggressive phenotypes of some cancer cells, including some head and neck cancers^{9,15}. By reviewing the data in Human Protein Atlas, we also confirmed that *HOXA10* expression is significantly higher in head and neck cancer tissues compared to the normal tissues (Figure 2A). Immunohistochemistry (IHC) staining of typically head and neck cancer tissue samples in the database showed moderate *HOXA10* staining mainly in the nucleus of the cancer cells (Figure 2B), suggesting that this transcription factor may exert regulative effect on gene expression. Then, using the TCGA database that includes 566 head and neck cancer patients, we compared the expression profiles of *HOXC6*, *HOXA3* and *HOXA10* and the top upregulated genes. Interestingly, we observed that *HOXA10*, but not *HOXC6* or *HOXA3* is positively correlated to *ZIC2* expression (Pearson's $r=0.5033$) (Figure 2C-D).

HOXA10 induces ZIC2 expression in NPC cells via binding to the promoter

Then, we investigated whether *HOXA10* has direct regulative effect on *ZIC2* expres-




Figure 2. ZIC2 expression is positively correlated to HOXA10 expression in head and neck cancer. **A**, The expression profile of HOXA10 in some cancers and the corresponding normal controls. Data was obtained from Human Protein Atlas. **B**, Typical IHC staining of HOXA10 in head and neck cancer tissues. Data was obtained from Human Protein Atlas. **C**, The heat map of HOXC6, HOXA3, HOXA10 and ZIC2 mRNA expression in 566 cases of head and neck cancer tissues. Data was obtained by analysis of head and neck cancer cohort of TCGA database using the UCSC Xena. **D**, Regression analysis of the expression between HOXA10 and ZIC2 based on the data in figure C.

sion in NPC cells. Both CNE1 and CNE2 cells were transfected with pCMV-HOXA10 expression vector for overexpression (Figure 3A-B). Following analysis showed that enforced *HOXA10* expression significantly elevated *ZIC2* expression at both mRNA and protein levels in both cell lines (Figure 3C-F). By performing bioinformatic prediction, we observed a HOXA10 binding site in the promoter region of *ZIC2* (Figure 3G-H). To further verify the possible binding, luciferase reporter constructs carrying the truncated *ZIC2* promoter sequences were generated. The following dual luciferase assay showed that the reporter plasmid carrying integrate HOXA10 binding site had significantly higher luciferase expression than other plasmids, while truncation of the predicted HOXA10 binding site significantly decreased the transcription activity (Figure 3I).

HOXA10 Promotes NPC Cancer cell Proliferation and Invasion via Inducing ZIC2 Expression

ZIC2 has been reported as an oncogene with regulative effect on cancer stem cell properties, cancer cell growth and invasion in some cancers^{12,13}. To demonstrate the functional role of

HOXA10 and *ZIC2* in NPC cells, CNE1 cells were transfected with pCMV-*HOXA10* or *ZIC2* shRNA alone or with pCMV-*HOXA10* and *ZIC2* shRNA in combination (Figure 4A). CCK-8 assay showed that *HOXA10* overexpression substantially increased CNE1 cell proliferation, while *ZIC2* knockdown significantly inhibited the proliferation. In addition, *ZIC2* knockdown partly counteracted the effect of *HOXA10* overexpression on facilitating cell proliferation (Figure 4B). Transwell assay also showed that *ZIC2* knockdown significantly reduced the invasion capability of CNE1 cells and also partly abrogated the effect of *HOXA10* overexpression on enhancing cell invasion (Figure 4C).

Discussion

Dysregulated transcription factors play important roles in pathological development of NPC via many different pathways. For example, *SOX4* overexpression was correlated with clinical stages, lymph node metastasis, and Ki-67 expression in NPC¹⁶. Functionally, *SOX4* can promote EMT of CNE2 cells and decrease the cisplatin sensitivity¹⁶. *SOX1* is downregulated in NPC due




Figure 3. HOXA10 induces ZIC2 expression in NPC cells via binding to the promoter. **A-D**, QRT-PCR analysis of HOXA10 (**A-B**) and ZIC2 (**C-D**) mRNA expression in CNE1 (**A** and **C**) and CNE2 (**B** and **D**) cells 24 h after transfection of pCMV-HOXA10 expression vector or the empty control. **E-F**, Western blot analysis of HOXA10 and ZIC2 protein expression in CNE1 and CNE2 cells 48 h after transfection of pCMV-HOXA10 expression vector or the empty control. **G-H**, HOXA10 binding positions (**G**) and the predicted HOXA10 binding site in the ZIC2 promoter (**H**). **I**, The luciferase reporter constructs carrying truncated ZIC2 promoter sequence were introduced into HEK-293 cells transfected with pCMV-HOXA10 expression vector or the empty control. Luciferase activity was measured 24 h post-transfection. **, $p < 0.01$.




Figure 4. HOXA10 promotes NPC cancer cell proliferation and invasion via inducing ZIC2 expression. **A**, Western blot analysis of ZIC2 expression in NES1 cells transfected with ZIC2 shRNA alone or were transfected with pCMV-HOXA10 or/and ZIC2 shRNA. **B-C**, CCK-8 assay of cell viability (**B**) and transwell assay of cell invasion (**C**) of NES1 cells transfected with pCMV-HOXA10 or/and ZIC2 shRNA. **, $p < 0.01$.

to promoter hypermethylation¹⁷. Restoration of *SOX1* expression in NPC cells can suppress colony formation, proliferation, migration and EMT *in vitro* and impair tumor growth in nude mice¹⁷.

The role of HOX family in NPC and other types of head and neck cancer has also been gradually revealed. The EBV product latent membrane protein 1 (LMP1) can silence *HOXC8* in NPC¹⁸.

Enforced *HOXC8* expression can inhibit NPC cell proliferation both *in vitro* and *in vivo* and can also modulate genes related to glycolysis and the expression of tricarboxylic acid (TCA) cycle¹⁸. *HOXD10* overexpression can decrease head and neck cancer cell invasion but increased proliferation, adhesion and migration¹⁹. De Barros et al²⁰ observed that *HOXC8*, *HOXD10*, and *HOXD11* genes might be critical for cell colony proliferation and cell migration of laryngeal squamous cell carcinoma.

In this report, by reviewing one publicly available microarray, we found that *HOXA10* is significantly upregulated in NPC tissues compared to normal controls. The IHC staining data in Human Protein Atlas also confirmed significantly higher *HOXA10* expression in head and neck cancer tissues than in normal tissues. However, the PPI analysis failed to identify any connections between *HOXA10* and the most upregulated genes. By data mining in head and neck cancer patient cohort in TCGA database, we observed that *ZIC2* expression is positively correlated to *HOXA10* expression. Since we identified a positive correlation between *HOXA10* and *ZIC2*, we decided to further investigate whether *HOXA10* has direct regulative effect on *ZIC2* expression. Our findings showed that *HOXA10* can directly bind to the promoter of *ZIC2* and upregulate *ZIC2* transcription.

ZIC2 has been demonstrated as an oncogene in multiple cancers. *ZIC2* overexpression can increase the growth rate and foci formation of epithelial ovarian cancer cells, while high *ZIC2* expression is associated with worse overall survival in stage I epithelial ovarian cancer¹². *ZIC2* can upregulate the expression of fibroblast growth factor receptor 3 (FGFR3) and Annexin A8 (ANXA8) in pancreatic cancer cells, leading to enhanced cellular proliferation and reduced cell apoptosis²¹. In liver cancer, *ZIC2* can drive the CSC properties via upregulating the expression of *OCT4*¹³. Since the role of *ZIC2* in NPC is not clear, we also investigated whether *ZIC2* has regulative effect on proliferation and invasion of NPC cells. Our data suggest that *ZIC2* knockdown significantly reduced cell proliferation and invasion capability of CNE1 cells and also partly abrogated the effect of *HOXA10* overexpression on enhancing cell proliferation and invasion.

Conclusions

Both *HOXA10* and *ZIC2* are upregulated in NPC tissues compared to the normal tissues. *HOXA10*

can increase *ZIC2* expression via binding to the *ZIC2* promoter. Functionally, the *HOXA10*-*ZIC2* axis can enhance NPC cell proliferation and invasion.

Conflict of interest

The authors declare no conflicts of interest.

References

- 1) CHANG ET, ADAMI HO. The enigmatic epidemiology of nasopharyngeal carcinoma. *Cancer Epidemiol Biomarkers Prev* 2006; 15: 1765-1777.
- 2) LOU F, MA HN, XU L, CHEN M, ZHU YB. Two polymorphisms of CD44 3'UTR weaken the binding of miRNAs and associate with naso-pharyngeal carcinoma in a Chinese population. *Eur Rev Med Pharmacol Sci* 2014; 18: 2444-2452.
- 3) YANG L, LIU L, XU Z, LIAO W, FENG D, DONG X, XU S, XIAO L, LU J, LUO X, TANG M, BODE AM, DONG Z, SUN L, CAO Y. EBV-LMP1 targeted DNAzyme enhances radiosensitivity by inhibiting tumor angiogenesis via the JNKs/HIF-1 pathway in nasopharyngeal carcinoma. *Oncotarget* 2015; 6: 5804-5817.
- 4) YANG F, LIU Q, HU CM. Epstein-Barr virus-encoded LMP1 increases miR-155 expression, which promotes radioresistance of nasopharyngeal carcinoma via suppressing UBQLN1. *Eur Rev Med Pharmacol Sci* 2015; 19: 4507-4515.
- 5) SPRATT DE, LEE N. Current and emerging treatment options for nasopharyngeal carcinoma. *Onco Targets Ther* 2012; 5: 297-308.
- 6) JIA WH, HUANG QH, LIAO J, YE W, SHUGART YY, LIU Q, CHEN LZ, LI YH, LIN X, WEN FL, ADAMI HO, ZENG Y, ZENG YX. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. *BMC Cancer* 2006; 6: 178.
- 7) BHATLEKAR S, FIELDS JZ, BOMAN BM. HOX genes and their role in the development of human cancers. *J Mol Med (Berl)* 2014; 92: 811-823.
- 8) CUI XP, QIN CK, ZHANG ZH, SU ZX, LIU X, WANG SK, TIAN XS. HOXA10 promotes cell invasion and MMP-3 expression via TGFbeta2-mediated activation of the p38 MAPK pathway in pancreatic cancer cells. *Dig Dis Sci* 2014; 59: 1442-1451.
- 9) LIBORIO-KIMURA TN, JUNG HM, CHAN EK. miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer. *Oral Oncol* 2015; 51: 151-157.
- 10) CARRERA M, BITU CC, DE OLIVEIRA CE, CERVIGNE NK, GRANER E, MANNINEN A, SALO T, COLETTA RD. HOXA10 controls proliferation, migration and invasion in oral squamous cell carcinoma. *Int J Clin Exp Pathol* 2015; 8: 3613-3623.
- 11) ALI RG, BELLCHAMBERS HM, ARKELL RM. Zinc fingers of the cerebellum (Zic): transcription factors and

- co-factors. *Int J Biochem Cell Biol* 2012; 44: 2065-2068.
- 12) MARCHINI S, POYNOR E, BARAKAT RR, CLIVIO L, CINQUINI M, FRUSCIO R, PORCU L, BUSSANI C, D'INCALCI M, ERBA E, ROMANO M, CATTORETTI G, KATSAROS D, KOFF A, LUZZATTO L. The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. *Clin Cancer Res* 2012; 18: 4313-4324.
- 13) ZHU P, WANG Y, HE L, HUANG G, DU Y, ZHANG G, YAN X, XIA P, YE B, WANG S, HAO L, WU J, FAN Z. ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. *J Clin Invest* 2015; 125: 3795-3808.
- 14) DODD LE, SENGUPTA S, CHEN IH, DEN BOON JA, CHENG YJ, WESTRA W, NEWTON MA, MITTL BF, MCSHANE L, CHEN CJ, AHLQUIST P, HILDESHEIM A. Genes involved in DNA repair and nitrosamine metabolism and those located on chromosome 14q32 are dysregulated in nasopharyngeal carcinoma. *Cancer Epidemiol Biomarkers Prev* 2006; 15: 2216-2225.
- 15) YAMATOJI M, KASAMATSU A, YAMANO Y, SAKUMA K, OGOSHI K, IYODA M, SHINOZUKA K, OGAWARA K, TAKIGUCHI Y, SHIIBA M, TANZAWA H, UZAWA K. State of homeobox A10 expression as a putative prognostic marker for oral squamous cell carcinoma. *Oncol Rep* 2010; 23: 61-67.
- 16) SHI S, CAO X, GU M, YOU B, SHAN Y, YOU Y. Upregulated expression of SOX4 is associated with tumor growth and metastasis in nasopharyngeal carcinoma. *Dis Markers* 2015; 2015: 658141.
- 17) GUAN Z, ZHANG J, WANG J, WANG H, ZHENG F, PENG J, XU Y, YAN M, LIU B, CUI B, HUANG Y, LIU Q. SOX1 down-regulates beta-catenin and reverses malignant phenotype in nasopharyngeal carcinoma. *Mol Cancer* 2014; 13: 257.
- 18) JIANG Y, YAN B, LAI W, SHI Y, XIAO D, JIA J, LIU S, LI H, LU J, LI Z, CHEN L, CHEN X, SUN L, MUEGGE K, CAO Y, TAO Y. Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8. *Oncogene* 2015; 34: 6079-6091.
- 19) HAKAMI F, DARDA L, STAFFORD P, WOLL P, LAMBERT DW, HUNTER KD. The roles of HOXD10 in the development and progression of head and neck squamous cell carcinoma (HNSCC). *Br J Cancer* 2014; 111: 807-816.
- 20) DE BARROS ELBR, RAMAO A, PINHEIRO DG, ALVES CP, KANNEN V, JUNGBLUTH AA, DE ARAUJO LF, MUYS BR, FONSECA AS, PLACA JR, PANEPUCCI RA, NEDER L, SAGGIORO FP, MAMEDE RC, FIGUEIREDO DL, SILVA WA, JR. HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma. *Tumour Biol* 2016; 37: 15087-15096.
- 21) INAGUMA S, ITO H, RIKU M, IKEDA H, KASAI K. Addiction of pancreatic cancer cells to zinc-finger transcription factor ZIC2. *Oncotarget* 2015; 6: 28257-28268.